Letter Agreement with 3i, Lp Dated 8-27-26
Valion Bio, Inc.
August 31, 2026
3i, LP
2 Wooster Street, 2nd Floor
New York, NY 10013
Attention: Maier J. Tarlow
| Re: | Side Letter — Closing under Series B Preferred Purchase Agreement and Series C Preferred Purchase Agreement |
Dear Mr. Tarlow:
This letter agreement (this “Letter Agreement”) is entered into as of the date first written above, by and between Valion Bio, Inc., a Delaware corporation (the “Company”), and 3i, LP, a Delaware limited partnership (the “Purchaser”).
The Company and the Purchaser are party to that certain Securities Purchase Agreement, dated April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the purchase and sale of up to 8,400 shares of the Company’s Series B Non-Voting Convertible Preferred Stock (“Series B Preferred Shares”) and warrants (“Series B Warrants”) to purchase a number of shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) at an initial exercise price determined pursuant to Section 2.2 of the Series B Preferred Purchase Agreement, for an aggregate purchase price of up to $8,400,000 in a series of closings. As of the date hereof, the Purchaser has the option, but not the obligation, to purchase up to 1,750 Series B Preferred Shares and corresponding Series B Warrants for up to
…